诺和诺德首席财务官卡斯滕・芒克・克努森在接受采访时表示公司正在关注肥胖症药物市场的潜在收购机会且凭借其资产负债状况拥有开

智通财经
Aug 06
诺和诺德首席财务官卡斯滕・芒克・克努森在接受采访时表示公司正在关注肥胖症药物市场的潜在收购机会且凭借其资产负债状况拥有开展交易的 “相当雄厚的实力”。这位首席财务官表示:“我们一直在寻求创新当然既包括内部创新也包括我们所涉足的治疗领域内的外部创新。”“在制药行业中我们是杠杆率最低的公司之一…… 因此单就我们的资产负债状况而言我们就拥有相当雄厚的实力。”他表示自己相信如果出现关键机遇诺和诺德的控股股东诺和诺德基金会将会 “非常支持”。不过诺和诺德凭借自身的资产负债状况即便 “不与基金会沟通”也有足够实力进行早期创新领域的收购。他认为诺和诺德没有必要从自身业务中 “进行任何有意义或大规模的剥离”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10